Gougerot-Sjögren
Veille bibliograhique : Gougerot-Sjögren
Les articles sont classés du plus ancien au plus récent, n’hésitez pas à utiliser la barre de recherche pour filtrer les résultats par date par exemple.
Theander E et al. Prediction of Sjögren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling. Arthritis Rheumatol. 2015 Sep;67(9):2427-36 | Lire le résumé |
Nocturne G et al. Rheumatoid Factor and Disease Activity. Are Independent Predictors of Lymphoma in Primary Sjögren’s Syndrome. Arthritis Rheumatol Hoboken NJ. avr 2016;68(4):977‑85. | Lire le résumé |
Baer AN et al. Association of Anticentromere Antibodies. With More Severe Exocrine Glandular Dysfunction in Sjögren’s Syndrome: Analysis of the Sjögren’s. International Collaborative Clinical Alliance Cohort. Arthritis Care Res. oct 2016;68(10):1554‑9 | Lire le résumé |
Bowman SJ et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren’s Syndrome. Arthritis Rheumatol Hoboken NJ. 2017 Jul;69(7):1440–50. | Lire le résumé |
Bootsma H et al. Editorial: Rituximab in the Treatment of Sjögren’s Syndrome: Is It the Right or Wrong Drug? Arthritis Rheumatol Hoboken NJ. 2017 Jul;69(7):1346–9. | Lire le résumé |
Bodewes ILA, Gottenberg J-E, van Helden-Meeuwsen CG, Mariette X, Versnel MA. Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren’s syndrome in the JOQUER randomized trial. Rheumatology [Internet]. 25 juin 2019 [cité 23 juill 2019]; Disponible sur: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/kez242/5523045 | Lire le résumé |
Felten R, Giannini M, Nespola B, Lannes B, Levy D, Seror R, et al. Refining myositis associated with primary Sjögren’s syndrome: data from the prospective cohort ASSESS. Rheumatology [Internet]. 11 août 2020 [cité 27 août 2020] | Lire le résumé |
Levy D, Nespola B, Giannini M, Felten R, Severac F, Varoquier C, et al. Significance of Sjögren’s syndrome and anti-cN1A antibody in myositis patients. Rheumatology [Internet]. 11 mai 2021 [cité 28 mai 2021]; | Lire le résumé |
Duret PM, Schleiss C, Kawka L, Meyer N, Ye T, Saraux A, et al. Bruton’s tyrosine kinase (BTK) gene overexpression is associated with risk of lymphoma in primary Sjögren’s syndrome. Arthritis Rheumatol Hoboken NJ. 28 avr 2023 | Lire le résumé |
Xu D, Fang J, Zhang S, Huang C, Huang C, Qin L, et al. Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatol Oxf Engl. 3 juill 2023;kead265 | Lire le résumé |
Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, et al. A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome. JCI Insight. 8 déc 2022;7(23):e163030. | Lire le résumé |
De Frémont GM, Costedoat-Chalumeau N, Lazaro E, Belkhir R, Guettrot-Imbert G, Morel N, et al. Pregnancy outcomes in women with primary Sjögren’s syndrome: an analysis of data from the multicentre, prospective, GR2 study. Lancet Rheumatol. juin 2023;5(6):e330‑40. | Lire le résumé |